China Summit Segment I: Opening Remarks / Key Regulatory and Policy Trends in Biopharmaceutical Innovation

2:00 PM - 3:15 PM, Monday, June 3, 2019 ・ 113ABC: Level 100
China’s ongoing regulatory and policy reforms will have a profound game-changing impact on its drug development innovation eco-system. Furthermore, while China has struggled in the past to achieve reimbursement for innovative medicines, we are also beginning to see significant paradigm shifts in the market access landscape in China. However, despite being the second largest pharmaceutical market, the trade war between U.S. and China have injected unpredictability and uncertainty into the landscape, notably with the recent investment restrictions, as well as proposed export controls. Join us at the Key Regulatory and Policy Trends panel for insights from our experts. 2:00 to 2:15pm China Summit Opening Remarks by Joe Damond, Executive VP for International Affairs, BIO 2:15 to 3:15pm Key Regulatory and Policy Trends in Biopharmaceutical Innovation Panelists: • Li Yan, Chief Medical Officer, Brii Biosciences • Ye Li, Vice President of Government Affairs and Policy, Merck Biopharma China • Jianqing Chang, Vice President, Drug Regulatory Policy, Tigermed • Jeannette Chu, Managing Director, PricewaterhouseCooper • Christian Davis, International Trae Partner, Akin Group Moderator: Josh Berlin, Executive Director, BioCentury
Vice President of Government Affairs and Policy
Merck Biopharma China
Chief Medical Officer
Brii Biosciences
Managing Director
Vice President, Drug Regulatory Policy
International Trade Partner
Akin Group